On Febuary 20, 2024, Imexpharm Pharmaceutical Joint Stock Company officially inaugurated its representative office in Ho Chi Minh City. This significant milestone marks a positive transformation in Imexpharm's operations, further strengthening its brand presence and recognition in major cities to better serve and support its customers, partners, and investors.
The Imexpharm leadership team performed the ribbon-cutting ceremony to inaugurate the office
Located on the 24th floor of Flemington Tower (Gia Bao Building), 184 Le Dai Hanh Street, District 11, the new representative office spans 600 square meters. Designed with a modern, open-space concept, it embodies sophistication and functionality. The office, prominently featuring Imexpharm’s signature blue branding color, is equipped with state-of-the-art IT systems and highly interactive workspaces to foster a dynamic and cohesive working environment for employees. The reception area is thoughtfully designed to create a welcoming atmosphere for customers, partners, and investors.
People’s Doctor, Pharmacist Tran Thi Dao, General Director of Imexpharm, speaks at the inauguration ceremony of the Ho Chi Minh City office.
Speaking at the inauguration ceremony, People’s Doctor, Pharmacist Tran Thi Dao, General Director of Imexpharm, stated: "As a company with over 45 years of history rooted in Đồng Tháp Province, Imexpharm is proud to have grown into one of Vietnam’s leading pharmaceutical manufacturers. With our development strategy and network expansion, the inauguration of our Ho Chi Minh City office demonstrates our commitment to increasing brand visibility in major cities and better serving our customers, partners, and investors.”
She further shared: "In the near future, Imexpharm plans to expand its network to the northern regions, providing high-quality, affordable healthcare products to hospitals, pharmacies, and the community. Beyond meeting domestic healthcare needs, we also aim to penetrate promising international markets. In January 2024, we successfully exported our first batch of antibiotics to Mongolia via air freight.”
Imexpharm employees working at the new representative office
To date, Imexpharm has established an extensive nationwide network across Northern, Central, and Southern Vietnam, including 20 sales branches, 2 branch offices in Ho Chi Minh City, and 2 central warehouses in Ho Chi Minh City and Đồng Tháp. The company operates 4 manufacturing clusters, with 3 EU-GMP-certified clusters encompassing 11 EU-GMP-standard production lines.
By the end of 2023, Imexpharm maintained double-digit growth, achieving total gross revenue of VND 2,113 billion, a 26% increase compared to the market’s overall 8% growth. Net revenue reached VND 1,994 billion, up 21% year-over-year. As of now, Imexpharm is ranked No. 1 in antibiotics in the Vietnamese market, surpassing both domestic and foreign competitors. In 2023, Imexpharm registered 11 additional EU Marketing Authorizations (MA) for 6 products, including complex formulations like Ampicillin/Sulbactam, raising its total to 27 EU MAs for 11 products.
In 2024, Imexpharm remains committed to driving growth by investing in initiatives to enhance productivity across its existing production lines and facilities. Simultaneously, the company is actively assessing the feasibility of new factory and production line projects to better address the evolving needs of both domestic and international markets.